Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

August 3, 2021

Immunic, Inc. to Participate in Investor Conferences in August
July 19, 2021

Immunic, Inc. Announces Closing of $45.0 Million Public Offering
July 15, 2021

Immunic, Inc. Announces Pricing of $45 Million Public Offering of Common Stock
July 14, 2021

Immunic, Inc. Announces Proposed Public Offering of Common Stock
July 12, 2021

Immunic, Inc. to Host Virtual R&D Day Today to Provide an Update on the Preclinical and Clinical Development of IMU-935, a Potentially Best-in-Class RORγt Inverse Agonist

- IMU-935 Has Been Observed In Vitro to Inhibit the Generation of Th17 Cells and Production of IL-17 Cytokines Without Impairing RORγt Function Required for Normal Thymocyte Development; May Avoid Risk of Lymphoma Formation Seen in Third-Party RORγt Programs -
July 1, 2021

Immunic, Inc. Announces FDA Clearance to Begin IMU-838 Phase 3 ENSURE Studies in Relapsing-Remitting Multiple Sclerosis and Phase 2 CALLIPER Study in Progressive Multiple Sclerosis

- Phase 3 ENSURE Program in Relapsing-Remitting Multiple Sclerosis (RRMS) Comprises Twin Studies Evaluating Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo, Intended to Provide Straightforward Path to Regulatory Approval -
June 28, 2021

Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in July
June 10, 2021

Immunic, Inc. to Participate in Industry and Investor Conferences in June
June 1, 2021

Immunic, Inc. Announces Appointment of Inderpal Singh as General Counsel
May 6, 2021

Immunic, Inc. Reports First Quarter 2021 Financial Results and Highlights Recent Activity

- EMPhASIS Cohort 2 Interim Analysis Confirmed 30 mg Dose of IMU-838 as Most Appropriate for Planned Phase 3 Program in Relapsing-Remitting Multiple Sclerosis, Expected to Begin in the Second Half of 2021 -

Show per page